SCHEMBL3766682

SCHEMBL3766682

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3ccnc(-c4cccc(N5CCOCC5)c4)c3)c2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.40
HDAC1 Q13547 1/20 0.40
JMJD6 Q6NYC1 1/20 0.39
PIK3CD O00329 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38
BUB1 O43683 1/20 0.38
CAMK2D Q13557 1/20 0.38
MAPK8 P45983 4/20 0.37
MAPK10 P53779 4/20 0.37
GABRA1 P14867 4/20 0.37
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRA5 P31644 4/20 0.37
GABRA3 P34903 4/20 0.37
GABRA2 P47869 4/20 0.37
MAPK9 P45984 1/20 0.36
JAK2 O60674 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760317 0.95 HTR1A (0.42) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL3766110 0.94 PRKCA (0.42) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL3754939 0.93 KDM1A (0.39) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL3764674 0.93 BUB1 (0.35) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL16162229 0.92 HRH4 (0.37) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL3756713 0.92 JAK2 (0.40) PIK3CDPIK3CAPIK3CBPIK3CGBUB1
SCHEMBL3756815 0.91 BUB1 (0.36) KDM1AHDAC1JMJD6PIK3CDPIK3CA
SCHEMBL3762158 0.91 LRRK2 (0.38) PIK3CDPIK3CAPIK3CBPIK3CGBUB1
SCHEMBL3764482 0.91 BUB1 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGBUB1
SCHEMBL3757704 0.91 PIK3CD (0.42) PIK3CDPIK3CAPIK3CBPIK3CGGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KDM1A 3543/4885HDAC1 669/4885JMJD6 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.